[go: up one dir, main page]

WO2006030402A2 - Dispositif d'administration osmotique a deux compartiments - Google Patents

Dispositif d'administration osmotique a deux compartiments Download PDF

Info

Publication number
WO2006030402A2
WO2006030402A2 PCT/IB2005/053076 IB2005053076W WO2006030402A2 WO 2006030402 A2 WO2006030402 A2 WO 2006030402A2 IB 2005053076 W IB2005053076 W IB 2005053076W WO 2006030402 A2 WO2006030402 A2 WO 2006030402A2
Authority
WO
WIPO (PCT)
Prior art keywords
delivery device
doxazosin
osmotic delivery
semipermeable membrane
osmotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/053076
Other languages
English (en)
Other versions
WO2006030402A3 (fr
Inventor
Rajan Kumar Verma
Narayanan Badri Viswanathan
Rajeev Singh Raghuvanshi
Ashok Kumar Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2006030402A2 publication Critical patent/WO2006030402A2/fr
Publication of WO2006030402A3 publication Critical patent/WO2006030402A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Definitions

  • the present invention relates to a dual compartment osmotic delivery devices and processes for their preparation.
  • Doxazosin is a quinazoline derivative that acts through selective inhibition of alpha- 1 adrenoceptors and is indicated for treating hypertension, either alone or in combination with other antihypertensive agents, and for the treatment of urinary outflow obstruction and symptoms associated with benign prostatic hyperplasia.
  • Doxazosin is well absorbed after oral administration with bioavailability of 65% and a mean plasma half- life of about eleven hours.
  • doxazosin therapy is initiated at a dosage of 1 mg standard immediate release dosage form per day and the dose is doubled every seven to fourteen days to a maximum recommended dose of 16 mg per day for hypertension and 8 mg per day for benign prostatic hyperplasia (BPH) till the blood pressure or urinary flow rate or BPH symptoms are controlled.
  • This regimen can require up to three to four titration steps to achieve therapeutically effective doses in a manner likely to avoid first dose side effects. This can be achieved by developing a formulation that gradually releases doxazosin resulting in a prolonged Tmax and reduced peak to trough blood level fluctuations of doxazosin as compared to the standard immediate release dosage form commercially available.
  • Osmotic delivery devices utilize osmotic pressure as the driving force for the delivery of the drug.
  • it includes an osmotic core that includes a drug with or without an osmotic agent.
  • the core is coated with a semipermeable membrane, and a delivery orifice is constructed with a mechanical or laser drill.
  • a delivery orifice is constructed with a mechanical or laser drill.
  • the bilayered tablet includes a drug layer and a push layer which is surrounded by a semipermeable membrane having an orifice.
  • the drug layer includes a gelling agent and a drug.
  • the gelling agent may include polymers capable of forming a gel when in contact with an aqueous medium.
  • the push layer includes an osmopolymer and osmotic agent.
  • the os- mopolymers are polymer(s) which are capable of swelling when in contact with aqueous medium and create an osmotic pressure gradient across the semipermeable membrane.
  • the choice of the polymers may vary depending on the molecular weight.
  • the polymers in the drug layer generally have a molecular weight lower than the polymers used in the push layer.
  • U.S. Patent Nos. 4,612,008;4,765,989; and 4,837,111 disclose various dual compartment osmotic devices.
  • the devices exemplified use polyethylene oxide in the push layer having molecular weight of about 5,000,000 to about 7,500,000.
  • U.S. Patent Nos. 4,946,687 and5,030,456 disclose dual compartment osmotic devices using polyethylene oxide in the push layer having a molecular weight of about 5,000,000 to about 7,800,000.
  • the osmotic system of the present invention includes a semipermeable wall that surrounds a compartment containing an active ingredient.
  • the wall is permeable to the passage of an external fluid but substantially impermeable to the passage of active in ⁇ gredients.
  • the device releases active ingredient by fluid being imbibed through the semipermeable wall into the compartment at a rate determined by the permeability of the semipermeable wall and the resulting osmotic pressure gradient across the semipermeable wall thereby dispensing the drug through the passageway or orifice in the device.
  • the dual compartment osmotic device of the present invention may provide several advantages over the monocompartment osmotic devices in delivering drugs with solubility extremes, for example, achieving zero order delivery kinetics and delivery of substantially all the drug into the target environment.
  • the device includes: a core comprising a drug layer, which includes one or more active ingredients, one or more gelling agents and, optionally, one or more pharmaceutically acceptable excipients; a push layer comprising polyethylene oxide having molecular weight of about 4,000,000 or lower and, optionally, one or more pharmaceutically acceptable excipients; a semipermeable membrane surrounding the core; and at least one passageway through the semipermeable membrane into the drug layer.
  • a drug layer which includes one or more active ingredients, one or more gelling agents and, optionally, one or more pharmaceutically acceptable excipients
  • a push layer comprising polyethylene oxide having molecular weight of about 4,000,000 or lower and, optionally, one or more pharmaceutically acceptable excipients
  • a semipermeable membrane surrounding the core; and at least one passageway through the semipermeable membrane into the drug layer.
  • Embodiments of the present invention may include one or more of the following features.
  • the active ingredient may be one or more of doxazosin, glipizide, isradipine, nifedipine, oxycodone, and methylphenidate.
  • the doxazosin may be co-processed doxazosin.
  • the co-processed doxazosin may include doxazosin and one or more wetting agents.
  • the doxazosin may be a salt of doxazosin.
  • the wetting agent may be one or more of polyethylene glycol, polyvinyl pyrrolidone, hydroxy propyl methyl cellulose and acrylate of methacrylate polymers.
  • the co-processed doxazosin may be doxazosin mesylate, and polyethylene glycol.
  • the gelling agents may be one or more of polyethylene oxide, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropyl methylcellulose, car- boxymethylcellulose, sodium alginate, guar gum, and xanthan gum.
  • the polyethylene oxide may have a molecular weight of 200,000.
  • the pharmaceutically acceptable excipients may be one or more of binders, osmotic agents, wetting agents, and lubricants.
  • the binder may be one or more of polyvinyl pyrrolidone, pregelatinised starch and hydroxypropyl methylcellulose.
  • the osmotic agent may be one or more of lactose, mannitol, sorbitol, sodium chloride, potassium chloride, magnesium chloride, sodium benzoate, sodium citrate, and glycine.
  • the wetting agent may be one or more of polyethylene glycol, propylene glycol, poloxamer, and polyoxyethylene sorbitan esters.
  • the lubricant may be one or more of magnesium stearate, zinc stearate, talc, and colloidal silicon dioxide.
  • the osmotic delivery device may also include one or more osmopolymers in the push layer.
  • the osmopolymer may be one or more of polyacrylic polymers, polymers of N- vinyl lactams, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxyethyl- cellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, cross linked car- boxymethylcellulose, sodium starch glycolate, sodium alginate, guar gum, xanthan gum, and copolymers of acrylic acid cross linked with a polyalkenyl polyether.
  • the osmotic delivery device may also include one or more non-functional coating layers below and/or above the semipermeable membrane.
  • a process for the preparation of a dual compartment osmotic delivery device includes: mixing one or more active ingredients, one or more gelling agents and, optionally, one or more pharma ⁇ ceutically acceptable excipients to obtain a drug layer blend; mixing polyethylene oxide having molecular weight of about 4,000,000 or lower, optionally one or more os ⁇ mopolymers and, optionally, one or more pharmaceutically acceptable excipients to obtain a push layer blend; compressing the drug layer blend and the push layer blend into bilayered tablet to obtain a core; coating the core with a semipermeable membrane; and drilling a passageway through the semipermeable membrane into the drug layer.
  • Embodiments of the present invention may include one or more of the following features.
  • the active ingredient may be one or more of doxazosin, glipizide, isradipine, nifedipine, oxycodone, and methylphenidate.
  • the doxazosin may be co-processed doxazosin.
  • the co-processed doxazosin may include doxazosin and one or more wetting agents.
  • a method of treating hypertension and/or benign prostatic hyperplasia in a mammal in need thereof includes ad ⁇ ministering a dual compartment osmotic delivery device.
  • the osmotic delivery device includes: a core comprising a drug layer comprising doxazosin, one or more gelling agents and, optionally, one or more pharmaceutically acceptable excipients; and a push layer comprising polyethylene oxide having molecular weight of about 4,000,000 or lower and, optionally, one or more pharmaceutically acceptable excipients; a semipermeable membrane surrounding the core; and at least one passageway through the semipermeable membrane into the drug layer.
  • the present invention provides a dual compartment osmotic delivery device.
  • the device includes a core that includes two layers.
  • the core includes a drug layer that includes an active ingredient, one or more gelling agents, and optionally, one or more pharmaceutically acceptable excipients.
  • the core includes a push layer that includes polyethylene oxide having a molecular weight of about 4,000,000 or lower and, optionally, one or more pharmaceutically acceptable excipients.
  • the core is surrounded by a semipermeable membrane and at least one passageway is constructed through the semipermeable membrane into the drug layer to deliver the active ingredient into the target environment.
  • the osmotic delivery device may further include one or more osmopolymers in the push layer.
  • the osmotic delivery device may also include one or more non-functional coating layers below or above the semipermeable membrane.
  • the active ingredient may include one or more of doxazosin, glipizide, isradipine, nifedipine, oxycodone, methylphenidate or any other water soluble or insoluble drug.
  • the active ingredient may be in the form of racemate, single enantiomer, salt, ester, solvate or mixtures thereof.
  • doxazosin mesylate may be used.
  • the active ingredient may be used alone or may co-processed with other excipients like wetting agents.
  • the term 'co-processed doxazosin' includes a mixture of doxazosin and one or more wetting agents.
  • Suitable wetting agents include one or more of polyethylene glycol, polyvinyl pyrrolidone, hydroxy propyl methylcellulose, acrylate of methacrylate polymers and mixtures thereof.
  • polyethylene glycol may be used.
  • Any wetting agent capable of increasing the dissolution rate and/or solubility of doxazosin in comparison to that without a wetting agent may be used in the present invention.
  • the push layer includes one or more osmopolymers with a molecular weight of less than 4,000,000.
  • Suitable osmopolymer include one or more of polyethylene oxide, polyacrylic polymers, polymers of N-vinyl lactams, polyvinylpyrrolidone, hydrox- ypropylcellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose, car- boxymethylcellulose, cross linked carboxymethylcellulose, sodium starch glycolate, sodium alginate, guar gum, xanthan gum, copolymers of acrylic acid cross linked with a polyalkenyl polyether and mixtures thereof.
  • a suitable polyethylene oxide for use in the push layer includes the polyethylene marketed by Dow under the trade name POLYOXTM. It is available in various grades depending on its molecular weight, which may range from about 100,000 to about 8,000,000. Examples of suitable grades of polyethylene oxide that may be used in the push layer include POLYOXTM WSR N-80 (MW - 200,000), WSR N-750 (MW - 300,000), WSR-205 (MW - 600,000), WSR-1105 (MW - 900,000), WSR N-12K (MW - 1,000,000), WSR N-60K (MW - 2,000,000) and WSR-301 (MW - 4,000,000). Combinations may be operable.
  • WSR N-80 MW - 200,000
  • WSR N-750 MW - 300,000
  • WSR-205 MW - 600,000
  • WSR-1105 MW - 900,000
  • WSR N-12K MW - 1,000,000
  • WSR N-60K MW - 2,000,000
  • the drug layer includes one or more gelling agents.
  • Suitable gelling agents include polyethylene oxide, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, sodium alginate, guar gum, xanthan gum and mixtures thereof.
  • the molecular weight of the gelling agent may be lower than that of the osmopolymer used in the push layer.
  • the gelling agent may be polyethylene oxide having a molecular weight of about 200,000 such as POLYOXTM WSR N-80.
  • Suitable pharmaceutically acceptable excipients include one or more of binders, osmotic agents, diluents, lubricants, wetting agents or solubilizing agents, absorption enhancers, emulsifiers, surfactants, swelling agents, pH modifiers, buffering agents, and coloring agents.
  • Suitable binders include one or more of polyvinyl pyrrolidone, pregelatinised starch, and hydroxypropyl methylcellulose.
  • Suitable osmotic agents may be any osmotically effective solute that is soluble in water and capable of exhibiting an osmotic pressure gradient across the wall against the external fluids.
  • Suitable osmotic agents include one or more of lactose, mannitol, sorbitol, sodium chloride, potassium chloride, magnesium chloride, sodium benzoate, sodium citrate, glycine, and mixtures thereof.
  • Suitable lubricants or glidants include one or more of magnesium stearate, zinc stearate, talc, and colloidal silicon dioxide.
  • Suitable wetting agents or solubilizing agents include one or more of polyethylene glycol, propylene glycol, poloxamer, polyoxyethylene sorbitan esters, and mixtures thereof.
  • Suitable coloring agents include any FDA approved colors for oral use.
  • the semipermeable membrane may include one or more semipermeable membrane- forming polymers and, optionally, one or more coating additives.
  • Suitable semipermeable membrane-forming polymers include one or more of cellulose derivatives, cellulose acetate, cellulose triacetate, agar acetate, amylose acetate, cellulose acetate ethyl carbamate, cellulose acetate phthalate, cellulose acetate methyl carbamate, cellulose acetate succinate, cellulose acetate dimethylaminoacetate, cellulose acetate ethyl carbonate, cellulose acetate chloroacetate, cellulose acetate ethyl oxalate, cellulose acetate methyl sulphonate, cellulose acetate butyl sulphonate, cellulose acetate propionate, cellulose acetate diethylamino-acetate, cellulose acetate octate, cellulose acetate laurate, cellulose acetate p-
  • the semipermeable membrane-forming polymer may be cellulose acetate.
  • the semipermeable membrane-forming polymer may be a combination of cellulose acetates having different degrees of acetylation.
  • the semipermeable membrane may be present at a concentration range from about 8% to about 20% w/w of the core or it may be present at a concentration range from about 10% to about 18% w/w.
  • Suitable coating additives include one or both of plasticizers and water soluble polymers.
  • Suitable plasticizers include one or more of polyethylene glycol, triethyl citrate, dibutyl sebacate, triethyl phosphate, diethyl tartrate and castor oil.
  • Suitable water soluble polymers include one or more of hydroxypropyl methylcellulose, hy- droxypropyl cellulose and polyvinyl pyrrolidone.
  • the core of the osmotic delivery device is preferably in the form of tablets.
  • the tablets may be prepared by any conventional tabletting technique including direct compression, wet granulation or dry granulation.
  • the tablets may be optionally coated with a non-functional coating below and/or above the semipermeable membrane.
  • the passageway through the semipermeable membrane may be any orifice, port, hole or opening that may be created manually or by laser drilling.
  • compositions of Co-processed doxazosin [47]
  • Example 1 [52] Core composition: [53]
  • the semipermeable coating composition is the same as that of Example 3 and the tablets were coated to a weight gain of 12% to 14% w/w.
  • step 2 The mixture of step 1 was granulated with polyvinylpyrrolidone solution, dried and sized through BSS #22 followed by blending with magnesium stearate, colloidal silicon dioxide, and talc to obtain a drug layer blend.
  • step 3 Polyethylene oxide of the push layer, sodium starch glycolate, sodium chloride, and red ferric oxide were mixed to obtain a mixture.
  • step 3 The mixture of step 3 was granulated with polyvinylpyrrolidone solution, dried and sized through BSS #22 followed by blending with magnesium stearate, colloidal silicon dioxide, and talc to obtain a push layer blend.
  • Example 18A The above coated tablets were further coated with the semipermeable coating composition of Example 3 to a weight gain of 13.51% w/w (Example 18A), 15.24%w/w (Examplel8B) and 17.42% w/w (Example 18C).
  • Example 19A The same process is followed as described in Example 18.
  • Example 19B The semipermeable coating composition is the same as that of Example 3 and the tablets were coated to a weight gain of 14.23% w/w (Example 19A), 15.06%w/w (Examplel9B) and 15.68% w/w (Example 19C).

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un dispositif d'administration osmotique à deux compartiments et des procédés d'élaboration correspondants.
PCT/IB2005/053076 2004-09-17 2005-09-19 Dispositif d'administration osmotique a deux compartiments Ceased WO2006030402A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1763/DEL/2004 2004-09-17
IN1763DE2004 2004-09-17

Publications (2)

Publication Number Publication Date
WO2006030402A2 true WO2006030402A2 (fr) 2006-03-23
WO2006030402A3 WO2006030402A3 (fr) 2006-05-18

Family

ID=35708749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/053076 Ceased WO2006030402A2 (fr) 2004-09-17 2005-09-19 Dispositif d'administration osmotique a deux compartiments

Country Status (1)

Country Link
WO (1) WO2006030402A2 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046114A3 (fr) * 2004-10-25 2006-10-26 Ranbaxy Lab Ltd Formes posologiques osmotiques a taux croissant de liberation du medicament, et leurs procedes de preparation
US8808745B2 (en) 2001-09-21 2014-08-19 Egalet Ltd. Morphine polymer release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
CN104224756A (zh) * 2014-09-26 2014-12-24 天津市聚星康华医药科技有限公司 一种甲磺酸多沙唑嗪口腔速溶膜及其制备方法
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
CN106727406A (zh) * 2017-01-04 2017-05-31 北京汇诚瑞祥医药技术有限公司 一种含多沙唑嗪的控释组合物及其制备方法
US9694080B2 (en) 2001-09-21 2017-07-04 Egalet Ltd. Polymer release system
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN115025058A (zh) * 2021-02-23 2022-09-09 成都同道慧宜生物医药科技有限公司 零级缓释药剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
JPH04503058A (ja) * 1989-01-30 1992-06-04 アルザ コーポレイション カルシウム拮抗体投与のための剤形
US5713852A (en) * 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8808745B2 (en) 2001-09-21 2014-08-19 Egalet Ltd. Morphine polymer release system
US9707179B2 (en) 2001-09-21 2017-07-18 Egalet Ltd. Opioid polymer release system
US9694080B2 (en) 2001-09-21 2017-07-04 Egalet Ltd. Polymer release system
US9375428B2 (en) 2003-03-26 2016-06-28 Egalet Ltd. Morphine controlled release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9884029B2 (en) 2003-03-26 2018-02-06 Egalet Ltd. Morphine controlled release system
WO2006046114A3 (fr) * 2004-10-25 2006-10-26 Ranbaxy Lab Ltd Formes posologiques osmotiques a taux croissant de liberation du medicament, et leurs procedes de preparation
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US9358295B2 (en) 2009-02-06 2016-06-07 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10639281B2 (en) 2013-08-12 2020-05-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10792254B2 (en) 2013-12-17 2020-10-06 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN104224756A (zh) * 2014-09-26 2014-12-24 天津市聚星康华医药科技有限公司 一种甲磺酸多沙唑嗪口腔速溶膜及其制备方法
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN106727406A (zh) * 2017-01-04 2017-05-31 北京汇诚瑞祥医药技术有限公司 一种含多沙唑嗪的控释组合物及其制备方法
CN115025058A (zh) * 2021-02-23 2022-09-09 成都同道慧宜生物医药科技有限公司 零级缓释药剂及其制备方法
CN115025058B (zh) * 2021-02-23 2024-01-26 成都同道慧宜生物医药科技有限公司 零级缓释药剂及其制备方法

Also Published As

Publication number Publication date
WO2006030402A3 (fr) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2006030402A2 (fr) Dispositif d'administration osmotique a deux compartiments
EP2010189B1 (fr) Dispositif osmotique d'administration d'un médicament comprenant un promoteur de la libération
ES2523145T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
HUP0402451A2 (hu) Készítmény és dózisforma hidrofil makromolekulák orális biohasznosíthatóságának fokozására
CZ17801U1 (cs) Perorální aplikacní forma s prodlouženým uvolnováním opioidu
EP1242055A1 (fr) Forme de dosage de medicament entraine par un hydrogel
AU621182B2 (en) Dosage form for administering calcium antagonist
CA2614085C (fr) Forme dosifiee pharmaceutique contenant une association de principes actifs de nifedipine et/ou de nisoldipine et un antagoniste de l'angiotensine-ii
TW200302748A (en) Osmotic delivery system
WO2015001488A1 (fr) Comprimés de palipéridone à libération prolongée et procédés de préparation
WO2006046114A2 (fr) Formes posologiques osmotiques a taux croissant de liberation du medicament, et leurs procedes de preparation
US20030219485A1 (en) Oral osmotic controlled drug delivery system
SK50572006U1 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
CN115715184A (zh) 替格瑞洛口服剂型及其制备方法
WO2008102235A1 (fr) Formulations d'alfuzosine à libération contrôlée
CN102058555A (zh) 一种多沙唑嗪控释片
HK1152864A (en) Once-a-day oxycodone formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase